Hisamitsu Pharmaceutical Co., Inc. (HTSUF) Stock

About Hisamitsu Pharmaceutical Co., Inc.

Hisamitsu Pharmaceutical Co., Inc. is a Japanese enterprise that develops and markets a range of pharmaceuticals, quasi-drugs, and medical devices. Its extensive product catalog includes popular external pain relief solutions such as SALONPAS, NOBINOBI, SALONSIP, AIR, and FEITAS. The company also provides targeted treatments like BUTENALOCK for athlete's foot and ALLEGRA FX, a medication addressing sinus and allergy symptoms. Furthermore, Hisamitsu produces various quasi-pharmaceuticals and cosmetic items. A core specialization lies in transdermal patch technology, offering analgesic anti-inflammatory patches like MOHRUS TAPE and MOHRUS PAP XR, alongside specialized patches for female hormone therapy, asthma management, and overactive bladder conditions. Their drug delivery systems also encompass FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Notably, Hisamitsu manufactures HFT-290, a transdermal patch utilized for cancer pain relief. Founded in 1847 and headquartered in Tosu, Japan, the company extends its sales reach to international markets, including the United States and various regions in Asia.

Hisamitsu Pharmaceutical Co., Inc. is headquartered in JP.

Hisamitsu Pharmaceutical Co., Inc. (HTSUF) stock trades at $29.00 with a market capitalization of $2.04B. The stock is valued at a price-to-earnings (P/E) ratio of 22.44, price-to-book of 1.46, price-to-sales of 2.61. Over the past 52 weeks the stock has ranged between $28.94 and $32.30, and currently trades 10.2% below its 52-week high. It pays a dividend yielding 2.86%.

On profitability, Hisamitsu Pharmaceutical Co., Inc. generates a return on equity (ROE) of 6.99%, return on capital employed of 5.66%, an operating margin of 10.99%, a net profit margin of 11.75%.

Official website: www.hisamitsu.co.jp